Bermekimab
Based on 1 Customer Validation
Bermekimab (MABp1) is a human monoclonal antibody targeting interleukin-1α(IL-1α) . Bermekimab can prevent tumor-related inflammation. Bermekimab can be used in the research of atopic dermatitis.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 97.68%
- CAS 番号: 1401965-15-8
- 分子量:145.5 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
Human IgG1 kappa
Human
IL1A
Bermekimab and promote healthy intestinal bacteria genera Akkermansia abundance increase related[2].
Bermekimab in colorectal cancer model can significantly improve the removal of the fat weight[3]
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Flow cytometric analysis of 1.5X106 THP-1 cells treated with 50 nM phorbol-12-myristate-13-acetate (PMA, HY-18739) and 5 μg/ml lipopolysaccharide (LPS, HY-D1056) for 24 hours with Bermekimab (HY-P99246, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃, Human IgG1 kappa, Isotype Control (HY-P99001, blue) was used as the isotype control ,cells without incubation with primary antibody were used as the unlabeled control (black).
化学情報
-
CAS 番号 1401965-15-8
-
性状 Liquid
-
分子量 145.5 kDa
-
Color Colorless to light yellow
-
SMILES
[Bermekimab]
-
別名
MABp1
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. McDonald JJ, et, al. Targeting IL-1α in cancer cachexia: a narrative review. Curr Opin Support Palliat Care. 2018 Dec;12(4):453-459. [Content Brief]
[2]. Gong J, et al. Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma. Sci Rep. 2022 Nov 4;12(1):18731. [Content Brief]
[3]. O'Sullivan Coyne G, et al. MABp1 for the treatment of colorectal cancer. Expert Opin Biol Ther. 2017 Sep;17(9):1155-1161. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)